High expression of Ku70 promotes proliferation of ovarian cancer cell lines and is associated with a poor prognosis for patients

doi:10.16352/j.issn.1001-6325.2022.09.1391

Abstract

Abstract: Objective To investigate the expression of X-ray-repaired cross complementary protein 6 (Ku70/XRCC6) in epithelial ovarian cancer(EOC) and its effects on the proliferation, apoptosis and migration of ovarian cancer cells. Methods Western blot was used to detect the expression of Ku70 in 9 ovarian cancer tissues of different grades and 3 normal ovarian tissues. Immunohistochemistry was used to detect the expression of Ku70 in 119 ovarian cancer tissues, and the relationship between Ku70 expression and clinicopathological parameters was analyzed. Kaplan-meier survival curve was used to analyze the relationship between Ku70 expression and 5-year survival. Colony formation and CCK-8 assay were used to analyze the effect of Ku70 expression on proliferation of ovarian cancer cells, and flow cytometry was used to detect the effect of Ku70 expression on apoptosis of ovarian cancer cells. The effect of Ku70 expression on ovarian cancer cell migration was analyzed by scratch test and Transwell chamber method. Results The expression of Ku70 in ovarian cancer tissues was higher than that in normal ovarian tissues. The expression of Ku70 was closely correlated with pathological features (P＜0.05). The survival rate of ovarian cancer patients with high Ku70 expression was lower than that of patients with low Ku70 expression(P＜0.05). Inhibiting the expression of Ku70 decreased poliferation and migration, and increased apoptosis of ovarian cancer cells (P＜0.05). Conclusions The abnormal expression of Ku70 is closely related to the occurrence of ovarian cancer and so Ku70 is a potential therapeutic target for ovarian cancer treatment.

Key words: Ku70/XRCC6, epithelial ovarian cancer, proliferation, apoptosis, migration

CLC Number:

R737.31

WANG Juan, ZHANG Xiao-yan, ZHU Ai-hua, YU Hong-bo, FAN Xin-dan, TANG Chun-hui, YAO Xiu-fang. High expression of Ku70 promotes proliferation of ovarian cancer cell lines and is associated with a poor prognosis for patients[J]. Basic & Clinical Medicine, 2022, 42(9): 1391-1399.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2022.09.1391

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2022/V42/I9/1391

References 12

[1]	Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer[J]. Lancet, 2019, 393: 1240-1253.
[2]	李家丽,刘颖. 非同源末端连接研究进展及其在肿瘤发生和治疗中的意义[J]. 基础医学与临床, 2019, 39: 899-903.
[3]	Jiang H, Lin Y, Yang CQ, et al. Quantitative assessment of the association between XRCC6 C1310G polymorphism and cancer risk[J]. Tumour Biol, 2013, 34: 779-785.
[4]	Li JJ, Gu QH, Li M, et al. Role of Ku70 and Bax in epigallocatechin-3-gallate-induced apoptosis of A549 cells in vivo[J]. Oncol Lett, 2013, 5: 101-106.
[5]	张妍,鞠桂芝,张坪,等.Ku70在宫颈癌组织中的表达及意义[J]. 中国妇幼保健, 2009, 24:1700-1702.
[6]	Rajaei M, Saadat I, Omidvari S, et al. Association between polymorphisms at promoters of XRCC5 and XRCC6 genes and risk of breast cancer[J]. Med Oncol, 2014, 31: 1-4.
[7]	Liu ZH, Wang N, Wang FQ, et al. High expression of XRCC5 is associated with metastasis through Wnt signal-ing pathway and predicts poor prognosis in patients with hepatocellular carcinoma[J]. Eur Rev Med Pharmacol Sci, 2019, 23: 7835-7847.
[8]	Coleman RL, Spirtos NM, Enserro D, et al. Secondary surgical cytoreduction for recurrent ovarian cancer[J]. N Engl J Med, 2019, 381: 1929-1939.
[9]	Hnizda A, Tesina P, Nguyen TB, et al. SAP domain forms a flexible part of DNA aperture in Ku70/80[J]. FEBS J, 2021, 288: 4382-4393.
[10]	Geng F, Zhang Y, Lu Z, et al. Fusobacterium nucleatum caused DNA damage and promoted cell proliferation by the Ku70/p53 pathway in oral cancer cells[J]. DNA Cell Biol, 2020, 39: 144-151.
[11]	Ihnen M, zu Eulenburg C, Kolarova T, et al. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer[J]. Mol Cancer Ther, 2013, 12: 1002-1015.
[12]	Pucci S, Mazzarelli P, Sesti F, et al. Interleukin-6 affects cell death escaping mechanisms acting on Bax-Ku70-Clusterin interactions in human colon cancer progression[J]. Cell Cycle, 2009, 8: 473-481.

[1]	HE Jing, LI Yan, WANG Yan-feng, BAO Hui. Up-expression of FABP4 promotes the proliferation and migration of endometrial cancer cell line HEC-1-A [J]. Basic & Clinical Medicine, 2022, 42(9): 1356-1361.
[2]	ZHANG Xiao-lei, LIU Jing, LI Chao-ping. Circ_0032821 is involved in sorafenib's inhibition of the proliferation, migration and invasion of breast cancer cell line T47D [J]. Basic & Clinical Medicine, 2022, 42(9): 1350-1354.
[3]	SHEN Yong-hua, WANG Jun-feng, CHENG Ze-xing, FENG Juan-juan. Esculin inhibits the proliferation of human nasopharyngeal carcinoma cell line HNE-3 [J]. Basic & Clinical Medicine, 2022, 42(8): 1237-1242.
[4]	ZHANG Min, XING Dan-dan, KANG Wen-yue, LIN Hui. Sevoflurane alleviates early brain injury in rats with subarachnoid hemorrhage [J]. Basic & Clinical Medicine, 2022, 42(8): 1206-1212.
[5]	XIE Si-an, CHEN Yi-yang, XU Jun-xuan, NING Ting-ting, ZHANG Nan, ZHU Sheng-tao, ZHANG Shu-tian. Effect of PTOV1 expression on prognosis of colorectal cancer patients [J]. Basic & Clinical Medicine, 2022, 42(8): 1176-1181.
[6]	XUE Jin-fang, SONG Hai-fei, CHEN Guo-bing. Research progress of programmed cell death in the occurrence and development of sepsis [J]. Basic & Clinical Medicine, 2022, 42(8): 1284-1287.
[7]	JIANG Ning, GUO Jun, LIU Cheng, ZHOU Ju. Curcumol inhibits proliferation and promotes apoptosis of human osteosarcoma cell lines [J]. Basic & Clinical Medicine, 2022, 42(8): 1200-1205.
[8]	LIU Lei, LI Shi-bao, ZHANG Hao-liang. Lnc-SLC2A12-10:1 silencing inhibits the proliferation, migration and invasion of gastric cancer cell line AGS [J]. Basic & Clinical Medicine, 2022, 42(7): 1071-1076.
[9]	ZHONG Ming, YU Xiu-yi, GUO Wei-xi, FANG Zheng. Ophiopogonin B inhibits proliferation and migration of human esophageal squamous cell carcinoma cell line EC9706 [J]. Basic & Clinical Medicine, 2022, 42(7): 1053-1059.
[10]	HAN Xue-ying, CUI Feng, LI Jun. Deleted in breast cancer 1(DBC1) affects the sensitivity of breast cancer cell lines to etoposide [J]. Basic & Clinical Medicine, 2022, 42(7): 1060-1066.
[11]	KANG You-li, ZHAO Dan, DU Wen-jing, LI Li. SIRT5 promotes the proliferation of human breast cancer cells by regulating the succinylation of ALDH5A1 [J]. Basic & Clinical Medicine, 2022, 42(7): 1099-1107.
[12]	BAI Bing, ZHANG Hai-fang, YANG Qing-liang, QIN Yue, ZHOU Chen-long, SONG Ge, WANG Ying. Down-regulation of lncRNA RHPN1-AS1 inhibits proliferation and migration of human bladder cancer cell line T24 [J]. Basic & Clinical Medicine, 2022, 42(6): 940-944.
[13]	SHA Wu-ga, LI Jun. High-throughput screening of inhibitors of NMNAT1 and their tumor-targeting functions [J]. Basic & Clinical Medicine, 2022, 42(6): 933-939.
[14]	GUO Jing, LI Ya-jie, MOU Han-shuang. LncRNA FGD5-AS1 reduces ox-LDL-induced damage of HUVECs by targeting miR-106a-5p [J]. Basic & Clinical Medicine, 2022, 42(5): 768-775.
[15]	HUANG Yun, XU Xi-sheng, CHEN Kai, HE Xiu. Down-regulation of lncRNA-H19 expression promotes apoptosis and autophagy of human keloid fibroblasts [J]. Basic & Clinical Medicine, 2022, 42(4): 633-639.